Dysregulated expression of tumor necrosis factor (TNF) has been implicated in multiple disease states, including asthma, allergy, arthritis, cardiovascular diseases, inflammatory bowel disease, diabetes, eczema, lupus, several different forms of cancer, and multiple infectious diseases including sepsis, tuberculosis (TB), and HIV-1. While TNF transcription is induced by a wide range of stimuli associated with cellular activation during infection, stress, and inflammation, work in our laboratory has shown that the mechanisms of TNF gene regulation are distinct for different cell types and for different stimuli. This exquisite cell-type and stimulus-specific transcription is directed by a highly conserved, compact, and modular proximal promoter region, where distinct sets of transcription factors assemble into higher order secondary structures, or enhanceosomes. More recently, we have shown that this specificity extends to the chromatin environment of the TNF locus, where conserved functional genetic regions are associated with cell type- and stimulus-specific DNase hypersensitivity sites (HSSs), intrachromosomal interactions, and interactions with the nuclear matrix. The identification of potential therapeutic targets to control TNF expression in specific cell types and in response to specific stimuli presents a highly attractive alternative to current TNF inhibitors that function in a non-specific, systemic fashion. The first hypothesis that will be tested in this proposal is that the cell type- and stimulus-specific chromatin environment of the TNF locus is a critical regulator in the control of TNF gene transcription in primary human cells. We will characterize the features of the chromatin environment of the TNF locus in human T cells and macrophages, including the location of constitutive and transient DNase I HSSs, histone modifications, protein-DNA contacts, and nucleosome positioning, associated with the stimulated and unstimulated state of these cells. Our studies will examine the impact of multiple physiologically relevant stimuli in T cells and monocytes. The second hypothesis that will be tested in this proposal is that specific factors establish higher-order chromatin interactions and impact DNA topology at the TNF locus in the control of TNF gene expression. We will determine the role of NFATp in the formation of activation-dependent intracrhomosomal interactions in T cells. Through integration of wild-type and mutant TNF/LT loci into cell lines, we will test the impact of specific HSSs upon TNF gene transcription. These cells type-specific HSSs contain matrix attachment regions that interact with topoisomerase II as well as a potential region involved in the transition of Z-to-B-form DNA. These HSSs potentially promote TNF gene transcription by counteracting transcription-induced supercoiling by flanking genes. Thus, these studies will not only elucidate novel mechanisms in the control of TNF gene regulation that may have broader implications for eukaryotic gene transcription, but also delineate potential clinical checkpoints for the control of TNF expression.

Public Health Relevance

Too much or too little tumor necrosis factor (TNF) protein influences a variety of diseases, including asthma, allergy, arthritis, sepsis, tuberculosis, and AIDS. Although current blockers of TNF have been used effectively in certain autoimmune diseases, these therapies are limited because of their lack of specificity and ensuing complications. By focusing our studies on the initial steps involved in the activation of the TNF gene in different kinds of cells, we hope to discover new therapeutic targets that allow for highly specific control of TNF protein levels.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM076685-08
Application #
8474780
Study Section
Innate Immunity and Inflammation Study Section (III)
Program Officer
Somers, Scott D
Project Start
2006-05-01
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
8
Fiscal Year
2013
Total Cost
$358,071
Indirect Cost
$153,459
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Chow, Nancy A; Jasenosky, Luke D; Goldfeld, Anne E (2014) A distal locus element mediates IFN-? priming of lipopolysaccharide-stimulated TNF gene expression. Cell Rep 9:1718-28
Falvo, James V; Jasenosky, Luke D; Kruidenier, Laurens et al. (2013) Epigenetic control of cytokine gene expression: regulation of the TNF/LT locus and T helper cell differentiation. Adv Immunol 118:37-128
Ranjbar, Shahin; Jasenosky, Luke D; Chow, Nancy et al. (2012) Regulation of Mycobacterium tuberculosis-dependent HIV-1 transcription reveals a new role for NFAT5 in the toll-like receptor pathway. PLoS Pathog 8:e1002620
Falvo, James V; Ranjbar, Shahin; Jasenosky, Luke D et al. (2011) Arc of a vicious circle: pathways activated by Mycobacterium tuberculosis that target the HIV-1 long terminal repeat. Am J Respir Cell Mol Biol 45:1116-24
Biglione, Sebastian; Tsytsykova, Alla V; Goldfeld, Anne E (2011) Monocyte-specific accessibility of a matrix attachment region in the tumor necrosis factor locus. J Biol Chem 286:44126-33
Falvo, James V; Tsytsykova, Alla V; Goldfeld, Anne E (2010) Transcriptional control of the TNF gene. Curr Dir Autoimmun 11:27-60
Tsytsykova, Alla V; Rajsbaum, Ricardo; Falvo, James V et al. (2007) Activation-dependent intrachromosomal interactions formed by the TNF gene promoter and two distal enhancers. Proc Natl Acad Sci U S A 104:16850-5
Tsytsykova, Alla V; Falvo, James V; Schmidt-Supprian, Marc et al. (2007) Post-induction, stimulus-specific regulation of tumor necrosis factor mRNA expression. J Biol Chem 282:11629-38
Baena, Andres; Mootnick, Alan R; Falvo, James V et al. (2007) Primate TNF promoters reveal markers of phylogeny and evolution of innate immunity. PLoS One 2:e621